Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron Inc. (NASDAQ: LGVN) announced that CEO Geoff Green will present on "A Regenerative Medicine Approach to Aging Frailty" at the Intercontinental Summit on Aging & Gerontology on March 8, 2021. The virtual summit, hosted by the Sciinov Group, aims to unite researchers and scientists to discuss advancements in Aging & Gerontology. Longeveron is focused on developing cellular therapies for aging-related conditions, including Alzheimer’s disease and Aging Frailty, through its investigational product LOMECEL-B™.
Longeveron (NASDAQ: LGVN) has appointed three new members to its Board of Directors: Douglas Losordo, M.D., Erin Borger, and Cathy Ross. Dr. Losordo brings over 20 years of biotech experience, previously serving in key roles at KBP Biosciences and Caladrius Biosciences. Erin Borger, a managing director at UBS Financial Services, has extensive experience in wealth management and medical board service. Cathy Ross boasts over 30 years in finance, including leadership roles at Fraud.Net and MotherNature.com. These appointments coincide with Longeveron's recent IPO, as it advances its mission in cellular therapies for aging-related diseases.
Longeveron Inc. (NASDAQ:LGVN) announced the pricing of its initial public offering (IPO) of 2,660,000 shares at $10.00 each, aiming for $26.6 million in gross proceeds before expenses. The IPO will close on February 17, 2021, with a 30-day option for underwriters to purchase an additional 399,000 shares. Trading on the Nasdaq starts February 12, 2021. The company's lead product, LOMECEL-B™, targets aging-related conditions. The SEC approved the registration statement on February 11, 2021.